Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.63 USD | +2.22% | -4.21% | +13.01% |
Feb. 27 | Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024 | |
Feb. 27 | Earnings Flash (MYGN) MYRIAD GENETICS Reports Q4 EPS $0.04, vs. Street Est of $0.01 | MT |
Business Summary
Number of employees: 2,700
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Hereditary Cancers
43.5
%
| 306 | 45.0 % | 328 | 43.5 % | +7.30% |
Prenatal
20.1
%
| 116 | 17.2 % | 151 | 20.1 % | +29.98% |
Pharmacogenomics
18.4
%
| 128 | 18.8 % | 139 | 18.4 % | +8.54% |
Tumor Profiling
18.0
%
| 129 | 19.0 % | 136 | 18.0 % | +5.44% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
89.2
%
| 592 | 87.2 % | 672 | 89.2 % | +13.56% |
Rest of World
10.8
%
| 87 | 12.8 % | 82 | 10.8 % | -6.21% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Diaz
CEO | Chief Executive Officer | 61 | 20-08-12 |
Scott Leffler
DFI | Director of Finance/CFO | 49 | Jan. 28 |
Dale Muzzey
CTO | Chief Tech/Sci/R&D Officer | 44 | 14-03-31 |
Thomas P. Slavin
CTO | Chief Tech/Sci/R&D Officer | - | 20-02-29 |
Kevin Haas
CTO | Chief Tech/Sci/R&D Officer | 38 | 18-07-31 |
Samraat Raha
COO | Chief Operating Officer | 52 | Dec. 10 |
Glenn Farrell
IRO | Public Communications Contact | - | 22-12-18 |
Matthew Scalo
IRC | Investor Relations Contact | - | 22-07-31 |
John Oberg
PRN | Corporate Officer/Principal | - | 23-01-02 |
Natalie Munk
AUD | Comptroller/Controller/Auditor | 43 | 20-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
S. Phanstiel
CHM | Chairman | 65 | 09-09-15 |
Paul Bisaro
BRD | Director/Board Member | 63 | 22-10-30 |
Dan Spiegelman
BRD | Director/Board Member | 65 | 20-05-26 |
Paul Diaz
CEO | Chief Executive Officer | 61 | 20-08-12 |
Lee Newcomer
BRD | Director/Board Member | 71 | 19-09-24 |
Colleen Reitan
BRD | Director/Board Member | 64 | 19-09-24 |
Heiner Dreismann
BRD | Director/Board Member | 69 | 10-06-09 |
Director/Board Member | 50 | 20-07-20 | |
Rashmi Kumar
BRD | Director/Board Member | 53 | 20-09-09 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 89,874,886 | 86,572,796 ( 96.33 %) | 0 | 96.33 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.01% | 1.9B | |
-2.52% | 12.56B | |
+6.04% | 9.03B | |
+9.74% | 5B | |
-35.53% | 4.33B | |
-8.84% | 3.99B | |
+10.88% | 2.76B | |
-0.26% | 2.57B | |
+14.30% | 1.81B | |
+8.53% | 1.72B |
- Stock
- Equities
- Stock Myriad Genetics, Inc. - Nasdaq
- Company Myriad Genetics, Inc.